The mission of the Foundation is to fund, promote, and support medical research dedicated to developing treatments and a cure for ML4.



Your donations directly support ML4 researchers at Harvard, Einstein, Baylor and other top academic institutions dedicated to finding treatments for Mucolipidosis Type IV.



What is ML4?

Mucolipidosis Type IV was first identified as a genetic lysosomal storage disease in 1974. Children with ML4 begin to exhibit developmental delays during the first year of life and many parents often pursue ophthalmologic evaluations for pseudo-strabismus.

Read more here

Our Mission

ML4 is a genetic disease causing developmental delays, retinal degeneration, gross and small motor dysfunction, and limited lifespan. The Foundation’s mission is to fund, support, and promote medical research dedicated to developing treatments and a cure for ML4.

Read more here

Patient Registry

If you or a family member have been diagnosed with ML4 or have not yet received a diagnosis, you are invited to participate in the CoRDS registry. Connect to the exciting science news and receive notifications of research opportunities for which you are eligible!

Read more here

The Latest News

Gene Therapy Advances

| Uncategorized | No Comments
The ML4 Foundation is funding several projects in gene therapy. One of these projects involves a collaboration between Dr. Steven Walkley (Einstein) and Dr. Charles Venditti (NIH). Read here about…

CoRDS patient registry a success!

| Uncategorized | No Comments
  Terrific enrollment by ML4 families in our CoRDS patient registry! In 2015, the ML4 Foundation launched our disease-specific patient registry with Sanford CoRDS. This registry contains clinical records by…

Funded Research

| Uncategorized | No Comments
The ML4 Foundation Board of Directors is pleased to report continued funding¬†to: Dr. Yulia Grishchuk (Massachusetts General Hospital) for her proposal, Targeting Neuroinflammation to Treat Mucolipidosis Type IV Dr. Tony… screens compounds for MLIV!

| Uncategorized | No Comments
Read about the exciting progress at in their efforts to screen for compounds to improve MLIV disease. "From Dead to Alive" certainly got our attention!